Table 2. Proportion of East Asian populations in large randomized clinical trials of acute coronary syndrome and AF.
| Study | Etiology | Drug | Total | Asian |
|---|---|---|---|---|
| TRILOGY | ACS | Prasugrel | 7,243 | 752 (8.1) |
| TRITON | ACS | Prasugrel | 13,608 | 1,905 (14.0) |
| PLATO | ACS | Ticagrelor | 18,624 | 1,096 (5.8) |
| RE-LY | AF | Dabigatran | 18,113 | 2,782 (15.3) |
| ROCKET AF | AF | Rivaroxaban | 14,264 | 932 (6.5) |
| ARISTOTLE | AF | Apixaban | 18,201 | 1,993 (10.9) |
| ENGAGE AF | AF | Edoxaban | 20,105 | 1,943 (9.6) |
Values are presented as number (%).
ACS = acute coronary syndrome; AF = atrial fibrillation; ARISTOTLE = Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation; ENGAGE = Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation; PLATO = PLATelet inhibition and patient Outcomes; RE-LY = Randomized Evaluation of Long-term anticoagulation therapY; ROCKET AF = Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation; TRILOGY = TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage; TRITON = TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel.